UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED 2211 股東週年大會適用之代表委任表格 本人╱吾等（姓名） （請以正楷填寫） 地址為 ， 為大健康國際集團控股有限公司（「本公司」）股本中每股面值0.1美元的股份 股 （參閱附註1） 的持有人， 茲委任（姓名） ， （地址） 或 （如其未能出席）（姓名） ， （地址） 或 （如其未能出席）大會主席 （參閱附註2） 為本人╱吾等的代表，代表本人╱吾等出席本公司謹訂於2025年12月11 日（星期四）上午十時正假座中國遼寧省瀋陽市鐵西區北一中路14-1號2樓會議室舉行的股東週年大會或其任何 續會，並代表本人╱吾等於會上就所提呈的任何決議案或動議進行投票。本人╱吾等的代表已獲授權及指示按 照下文所示 （參閱附註3） 就下列決議案投票： 2. 股東可自行委任多於一名代表，如欲作出此項委任，請將「大會主席」字樣刪去，並在空欄內填上所委任代表的姓名。本代表委任表格的任何更正，均須由簽署 人簡簽作實。 3. 重要提示： 閣下如欲投票贊成任何決議案，請在有關決議案的「贊成」欄內填上「✔」號。 閣下如欲投票反對任何決議案 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED 2211 股東週年大會通告 茲通告大健康國際集團控股有限公司（「本公司」）謹訂於2025年12月11日（星期四）上午十 時正假座中國遼寧省瀋陽市鐵西區北一中路14-1號2樓會議室召開股東週年大會（「大 會」），以考慮及酌情通過（不論有否作出修訂）本公司的下列普通決議案： 普通決議案 - 1 - 1. 省覽及採納本公司及其附屬公司截至2025年6月30日止年度的經審計合併財務報表以 及本公司董事會報告與核數師報告。 2. (a) 重選本公司以下退任董事： (i) 初川富先生為執行董事 (ii) 鄭雙慶先生為獨立非執行董事 (iii) 江素惠女士為獨立非執行董事 (b) 授權本公司董事會（「董事會」）釐定本公司董事的酬金。 - 2 - (iv) 就本決議案而言： (a) 「有關期間」指自本決議案獲通過當 ...

此乃要件 請即處理 閣下如對本通函或應採取的行動有任何疑問，應諮詢 閣下的股票經紀或其他註冊證券交易 商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已出售或轉讓名下所有大健康國際集團控股有限公司股份，應立即將本通函連同隨附代 表委任表格交予買主或承讓人，或經手買賣或轉讓的銀行、持牌證券交易商或其他代理商，以 便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED 2211 (1)建議授出發行股份及回購股份之一般授權； (2)重選退任董事； (3)建議修訂組織章程細則； 及 (4)股東週年大會通告 本通函封面下半部分及首頁所用詞彙與本通函「釋義」一節所界定者具有相同涵義。 2025年股東週年大會於2025年12月11日（星期四）上午十時正假座中國遼寧省瀋陽市鐵西區北 一中路14-1號2樓會議室舉行，大會通告載於本通函第AGM- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED 2211 建議修訂現有的組織章程細則 及 建議採納新組織章程細則 本公告乃由大健康國際集團控股有限公司（「本公司」）根據香港聯合交易所有限公司證券 上市規則（「上市規則」）第13.51(1)條作出。 本公司董事（「董事」）會（「董事會」）建議修訂本公司現有經修訂及重列組織章程細則（「組 織章程細則」），以（其中包括）使組織章程細則符合上市規則之修訂及開曼群島適用法例 的修訂（「建議修訂」），並透過採納新的組織章程細則（「新組織章程細則」），將所有建議 修訂納入並合併，以全面取代及廢除組織章程細則。 建議修訂概述如下： 1. 促進電子通訊：規定允許使用電子通訊方式發送通知及文件（包括財務報表），准許 以電子方式簽立代表委任文據，以及本公司以電子方式簽立任何通知或文件。本公 司股東（「股東」）現在可以透 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 大健康國際集團控股有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02211 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.1 | USD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 500,000,000 | USD | | 0.1 | USD | | 50,000,000 | FF301 F ...

Core Insights - ST Hongda (002211.SZ) reported its Q3 2025 results, revealing that four institutional investors hold a total of 68.71 million shares, representing 15.89% of the company's total equity [1] - The institutional holding percentage decreased by 22.58 percentage points compared to the previous quarter [1] - Foreign investment sentiment showed a slight increase, with Morgan Stanley & Co. International PLC increasing its holdings by 0.23% [1] - A new foreign institution, Goldman Sachs International - Proprietary Capital, was disclosed this quarter, while UBS AG and Barclays Bank PLC were not reported [1] Institutional Holdings - Four institutional investors disclosed holdings in ST Hongda, totaling 68.71 million shares, which is 15.89% of the total share capital [1] - The overall institutional holding percentage saw a significant decline of 22.58 percentage points from the last quarter [1] Foreign Investment - One foreign fund, Morgan Stanley & Co. International PLC, increased its holdings by 0.23% compared to the previous period [1] - A new foreign institution, Goldman Sachs International - Proprietary Capital, was reported this quarter [1] - UBS AG and Barclays Bank PLC were not disclosed in this quarter's report [1]

Business Operations - The Group operates 120 retail pharmacies primarily located in Northeast China, with approximately 1,027 active distributors and 842 full-time staff[8]. - The Group has established 3 large-scale distribution logistics centers in Shijiazhuang, Harbin, and Jiamusi, enhancing its national distribution system[8]. - The main product categories include prescribed drugs, non-prescribed drugs, traditional Chinese medicine, and health care products, among others[9]. - The Group aims to expand its product mix by introducing more health care products based on its expertise in pharmaceutical retail and distribution[11]. - The Group is actively exploring online pharmacies, cross-border e-commerce, and influencer marketing as part of its "Internet+" strategy[12]. - The Group emphasizes the concept of "Specialization+" and "Platform+" to enhance its business model and cope with the "New Norm" in the real economy[12]. - The Group is focused on upgrading and digital transformation within the industry to maintain its competitive edge[12]. - The Group's strategy includes leveraging core advantages of branded products and expanding cooperation in this area[11]. - The Group is committed to developing the upstream ecological chain, including the construction of Chinese herbal medicine bases[11]. - The Group's vision is to become a leading international brand operator in the universal health industry[7]. Financial Performance - Revenue for the year ended June 30, 2025, was RMB 711.5 million, a decrease of 34.7% from RMB 1,089.0 million in 2024[20]. - Gross profit decreased by 37.0% to RMB 113.4 million from RMB 179.9 million[20]. - The company reported an operating loss of RMB 25.5 million, compared to a profit of RMB 0.1 million in the previous year[20]. - Basic loss per share was RMB (32.46) cents, down from RMB 0.62 cents in 2024, representing a decline of 33.08 cents[20]. - The current ratio improved to 1.3 times from 1.0 times, indicating better short-term financial health[20]. - Trade receivables turnover days increased to 33.4 days from 27.8 days, reflecting slower collection of receivables[20]. - The total number of stores as of June 30, 2025, was 120, with 83 stores closed during the year due to lower profitability[32]. - The company is focusing on optimizing its business model and improving operational efficiency in response to market changes[31]. - The Group's retail business revenue was RMB 197.9 million for the Year, representing a year-on-year decrease of 40.4%[60]. - The nationwide distribution business revenue was RMB 513.6 million, a year-on-year decrease of 32.1%[64]. - The Group operated a total of 223 branded products at the end of the Year, following a net reduction of 315 branded products[67]. - The Group had a total of 120 chain stores at the end of the Year, down from 203 in 2024[60]. - The distribution segment revenue decreased by 32.1% to RMB 513.6 million, while retail segment revenue fell by 40.4% to RMB 197.9 million[90]. Market Trends and Strategies - Future industry development is expected to focus on precision medicine, digital health, and the elderly care economy[29]. - The global GDP growth is predicted to slow down to about 2.3% in 2025, impacting operational strategies[29]. - The market size of China's healthcare industry is expected to reach RMB 29.1 trillion by 2030[44]. - The Group aims to enhance its strength and improve the product line-up through the development of integrated outpatient services[37]. - The Chinese government has prioritized the development of the traditional Chinese medicine (TCM) industry, introducing supportive policies to promote high-quality development[45]. - The application of artificial intelligence in disease diagnosis and health management has improved efficiency and accuracy in the healthcare sector[48]. - The PRC has accelerated the construction of the elderly care service system, enhancing service quality and management levels in 2024[50]. - Investment in preventive medicine has increased, focusing on vaccine research and health education to reduce disease occurrence[51]. - The demand for healthcare and elderly care services is continuously growing due to an aging population and increased health awareness[48]. Corporate Responsibility and Sustainability - The Group is committed to corporate responsibility, focusing on environmental, social, and governance aspects to enhance long-term competitiveness[38]. - The company is committed to enhancing sustainability practices and addressing climate impact through ambitious environmental goals[151]. - The company aims to create value for stakeholders through responsible operations, focusing on environmental, operational, and community factors[152]. - The company engages with various stakeholders, including government regulators and investors, to ensure compliance and transparency[156]. - The company actively participates in community welfare projects and addresses social responsibilities[156]. - The Group's emission indicators for the year ended June 30, 2024, include 301.6 kg of nitrogen oxides (NOx) and 90,188.9 kg of carbon dioxide (CO2) with respective emission/revenue ratios of 0.424 and 126.8[163]. - The Group's resource usage for the year ended June 30, 2024, includes 342,208 degrees of electricity, 38,216 liters of petrol, and 1,745 m³ of water, with usage/revenue ratios of 481.0, 53.7, and 2.5 respectively[177]. - The Group actively promotes energy-saving and emission reduction measures among its manufacturers, ensuring compliance with national environmental protection regulations[165]. - The Group has reduced business trips to lower energy consumption and greenhouse gas emissions, utilizing teleconferencing as an alternative[164]. - The Group's commitment to environmental protection includes a "green office" initiative aimed at saving electricity and water through employee awareness and behavior changes[170]. - The Group's policies for energy and water conservation provide specific guidance to employees on reducing environmental impact[179]. - The Group's transportation strategy prioritizes local suppliers to minimize energy consumption during the transportation process[158]. - The Group's environmental initiatives include promoting electronic documentation to reduce paper usage and implementing a paperless office policy[171]. Employee Management and Training - As of June 30, 2025, the Group had 842 employees, with 99.0% located in mainland China[185]. - The employee turnover rate for general staff aged 50 and above was 38.5%, while for those aged 40-49 it was 40.2%[196]. - The Group's management has implemented strict compliance with local employment laws, ensuring fair treatment regardless of nationality, race, gender, or age[186]. - The Group provides environmental protection training for new employees and actively promotes green purchasing practices[181]. - The Group's compensation structure links a portion of employee pay to individual and overall performance, incentivizing high performance[189]. - The Group has a zero-tolerance policy for child labor and forced labor, conducting strict recruitment examinations to prevent such practices[188]. - The Group has established management policies and procedures for human resources to ensure an ideal and safe working environment for employees[198]. - The Group implements national regulations on occupational safety and provides necessary labor protection resources, including white gowns for sales personnel[199]. - Regular monitoring of compliance status is conducted, including checks on fire-fighting equipment and air quality maintenance[199]. - The Group provides social insurance for employees, including employment injury insurance, and liability insurance for directors and senior management[199]. Strategic Initiatives and Future Plans - The Group plans to divest non-primary businesses and optimize store layout to adapt to the competitive pharmaceutical market[37]. - The "Specialization+" strategy will be implemented to improve service professionalism and operational quality, leveraging licensed pharmacists and business institute advantages[134][136]. - The "Platform+" strategy aims to expand value-added services in stores to meet increasing consumer health demands, adapting to new market conditions[137]. - The "Internet+" strategy will strengthen the integration of online and offline services, utilizing mobile internet technologies and e-commerce partnerships[139][140]. - A subscription agreement was entered into on May 13, 2025, for 30,440,263 new shares at HK$0.80 per share, raising approximately HK$24.35 million[141][142]. - The company plans to enhance the integration of online and offline operations through its "Internet+" strategy, leveraging mobile internet applications and new marketing ecosystems[143]. - A total of 30,440,263 new shares were issued at a subscription price of HK$0.80 per share, raising approximately HK$24.35 million[144]. - The authorized share capital will increase from US$10 million to US$50 million, allowing for greater flexibility in future fundraising efforts[146]. - The increase in authorized share capital was approved by shareholders on August 19, 2025, and became effective the same day[147].

截至月份: 2025年9月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 大健康國際集團控股有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02211 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.1 | USD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 500,000,000 | USD | | 0.1 | USD | | 50,000,000 | 本月底法定/註冊 ...

Core Viewpoint - The company reported a significant decline in revenue and an increase in losses for the fiscal year ending June 30, 2025, primarily due to the impact of new healthcare policies in China [1] Financial Performance - The company recorded revenue of RMB 710 million, a year-on-year decrease of 34.7% [1] - The loss attributable to shareholders was RMB 26 million, compared to a profit of RMB 400,000 in 2024 [1] - Earnings per share were RMB -0.3246, a decline from an adjusted profit of RMB 0.0062 per share in 2024 [1] Market and Operational Challenges - Revenue decline was attributed to the new healthcare policies in China and a decrease in the number of active customers within the national distribution network [1] - The company is actively participating in alliance activities to enhance its industry influence and brand product development [1] Strategic Initiatives - The company is focusing on national strategic initiatives such as "Healthy China," "Beautiful China," "Belt and Road," "Guangdong-Hong Kong-Macao Greater Bay Area," and "Hainan Free Trade Port" to guide its business transformation and upgrade [1] - The company aims to leverage industry experience and focus on technological innovation to explore further business transformation directions [1]

Core Points - The company reported a revenue of approximately 711.5 million, representing a year-on-year decrease of 34.7% [1] - Gross profit was approximately 113.4 million, down 37% year-on-year [1] - The company recorded a loss attributable to owners of 26.06 million, marking a shift from profit to loss compared to the previous year [1] - Earnings per share were reported at a loss of 32.46 cents [1] Revenue Analysis - The decline in revenue is primarily attributed to the impact of new healthcare insurance policies in China [1] - Additionally, there was a decrease in the number of active customers within the national distribution network [1]